AIM ImmunoTech expects Q1 2027 topline data from Phase 2 DURIPANC trial
AIM•AIM ImmunoTech expects topline data in Q1 2027 from its Phase 2 DURIPANC trial testing Ampligen with durvalumab in metastatic pancreatic cancer. Overall survival analysis is expected to start in Q3 2027.
1. Trial timeline
AIM ImmunoTech said its ongoing Phase 2 DURIPANC study is testing Ampligen with AstraZeneca’s durvalumab in metastatic pancreatic cancer. Topline results have not been presented, and the company expects them in Q1 2027, with overall survival analysis starting in Q3 2027. An earlier named-patient experience suggested longer survival for selected patients who received Ampligen as maintenance; the company described neutrophil-to-lymphocyte ratio as a potential patient-selection tool pending confirmation.
